NanoVibronix Inc (NAOV)
NanoVibronix Inc Notification (NAOV)
SELLAS Life Sciences Group Inc. (SLS)
SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes
UG Healthcare Corporation Limited (8K7)
Retirement Of Executive Director And Change Of Composition Of The Board Of Directors
iBio Inc. (IBIO)
Phio Pharmaceuticals Corp. (PHIO)
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Nektar Therapeutics (NKTR)
OPTIMIZERx Corp (OPRX)
New Form 8-K - OptimizeRx Corp Filed: 2025-06-24 AccNo: 0001213900-25-056908 Size: 215 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Nektar Therapeutics (NKTR)
REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis
Incannex Healthcare Ltd (IXHL)
Abeona Therapeutics Inc. (ABEO)
Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa
Incannex Healthcare Ltd (IXHL)
Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch
Regeneron Pharmaceuticals Inc (REGN)
Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization
OPTIMIZERx Corp (OPRX)
OptimizeRx Corporation Appoints CEO Steve Silvestro to Board of Directors
Plus Therapeutics Inc (PSTV)
Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing
Lexeo Therapeutics Inc. (LXEO)
Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics